PMGC Holdings (ELAB) Operating Expenses (2022 - 2026)
PMGC Holdings (ELAB) posted Operating Expenses of $3.6 million for Q1 2026, up 38.39% sequentially from $2.6 million in Q4 2025.
PMGC Holdings (ELAB) Operating Expenses (2022 - 2026) Analysis & Trends
PMGC Holdings has reported Operating Expenses for 5 years, with the latest figure at $3.6 million in Q1 2026.
- Quarterly Operating Expenses changed N/A year-over-year to $3.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.4 million (up 448.45% YoY) and the FY2025 annual result came in at $7.1 million, up 92.91% from the prior year.
- Operating Expenses rose to $3.6 million in Q1 2026 per ELAB's latest filing, from $2.6 million in the prior quarter.
- Over five years, Operating Expenses peaked at $709.5 million in Q3 2022 and troughed at -$1.5 billion in Q4 2022.
- A 5-year average of -$57.3 million and a median of $1.3 million in 2024 frame the typical range for Operating Expenses.
- The widest YoY moves for Operating Expenses: up 792.91% in 2024, down 205.48% in 2024.
- Over 5 years, Operating Expenses stood at -$1.5 billion in 2022, then soared by 100.11% to $1.5 million in 2023, then tumbled by 205.48% to -$1.6 million in 2024, then surged by 258.26% to $2.6 million in 2025, then soared by 38.39% to $3.6 million in 2026.
- According to Business Quant data, Operating Expenses over the past three periods registered $3.6 million, $2.6 million, and $2.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | PMGC Holdings | 3.01 Mn | -15.78 Mn | 385,691.00 | 4.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.56 Mn |
| Dec 31, 2025 | 2.58 Mn |
| Sep 30, 2025 | 2.28 Mn |
| Dec 31, 2024 | -1.63 Mn |
| Sep 30, 2024 | 1.31 Mn |
| Jun 30, 2024 | 1.85 Mn |
| Mar 31, 2024 | 23,537.00 |
| Dec 31, 2023 | 1.54 Mn |
| Sep 30, 2023 | 1.15 Mn |
| Jun 30, 2023 | 1.26 Mn |
| Mar 31, 2023 | 2,636.00 |
| Dec 31, 2022 | -1.47 Bn |
| Sep 30, 2022 | 709.53 Mn |